罕见的头部和部癌症和病理诊断挑战:综合文献综述
Daria Maria Filippini1,2, Francesca Carosi1, Giulia Querzoli2,3
1Division of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria Sant'Orsola Malpighi, 40138 Bologna, Italy.
Diagnostics (Basel, Switzerland)
|November 9, 2024
概括
罕见的头癌 (R-HNCs) 存在诊断方面的挑战. 本综述强调了个性化治疗的关键组织病理学和分子特征,包括最近的全身疗法进展.
科学领域:
- 在瘤学瘤学.
- 病理学 病理学 病理学
背景情况:
- 头癌 (HNCs) 除了状细胞癌 (SCC) 之外,还包括各种组织学.
- 罕见的HNCs (R-HNCs) 包括上皮和非上皮瘤,带来独特的诊断和治疗挑战.
研究的目的:
- 为提供关于罕见头癌的综合文献综述.
- 强调关键的组织病理学和分子特征,以指导治疗决策.
- 报告R-HNC系统治疗的最新进展.
主要方法:
- 关于罕见的头癌的综合文献综述.
- 专注于组织病理学和分子特征.
- 包括当前的全身治疗发展.
主要成果:
- R-HNCs需要专门的组织病理学专业知识和分子分析.
- 个性化治疗策略是必不可少的,由多学科瘤委员会指导.
- 系统疗法的最新发展为治疗提供了新的途径.
结论:
- 有效管理R-HNC需要对其特定特征有深入的了解.
- 多学科合作和量身定制的治疗对于改善患者的治疗结果至关重要.
- 对分子驱动因素和全身疗法的持续研究对于推进R-HNC护理至关重要.
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...


